Dr Cook on Real-World Data With Bridging Therapy and Axi-Cel in Relapsed/Refractory LBCL
Michael R. Cook, MD, discusses real-world data associated with the utilization of bridging therapy prior to treatment with axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma.
Michaelr Cook Abramson Cancer Center Penn Presbyterian Real World Data With Bridging Therapy Penn Medicine Ash Annual Meeting And Exposition Onclive Tv
Source: onclive.com